Document Detail

When less is better: the safety and efficacy of reduced intensity gemcitabine in a difficult patient population with advanced non-small-cell lung cancer.
MedLine Citation:
PMID:  23322519     Owner:  NLM     Status:  In-Data-Review    
Treatment of elderly or poor performance status (PS) patients with advanced non-small-cell lung cancer (NSCLC) is a debated topic. To evaluate the efficacy of a modified schedule of gemcitabine, 59 patients unfit for platinum were enrolled. Mean age was 75.8 years and 41 % of patients had an ECOG PS 2. Gemcitabine was given at 1000 mg/m(2) on days 1, 8 each 28. Most of patients received gemcitabine as first-line chemotherapy, which was continued as maintenance over 6 cycles in responding and stable patients. Median overall survival (OS) and progression-free survival (PFS) were 7.2 and 5 months. In those 45 evaluable patients, treatment resulted in 1 complete remission (CR), 9 partial remissions (PR), and 20 stable diseases (SDs) with a response rate (CR + PR) of 22 % and a clinical benefit (CR + PR + SD) of 68 %. Gemcitabine was continued over 6 cycles in 16 patients (27 %). These patients were treated until progression with a mean of further 8.6 cycles. Median OS and PFS in these selected patients were 19 and 16 months. The toxicity profile was excellent with only 8 % of overall G3-G4 adverse events. None of the 16 patients under the maintenance phase reported significant toxicity. Gemcitabine given at a lower dose intensity than standard should be considered as valuable therapeutic option in elderly or poor PS patients with advanced NSCLC unfit for platinum. Extending the treatment beyond 6 cycles in responding patients is feasible and may prolong survival.
A Nacci; N Calvani; P Rizzo; P Fedele; L Orlando; P Schiavone; M Cinefra; A Marino; F Sponziello; M D'Amico; S Cinieri
Related Documents :
9153099 - Cricohyoidoepiglottopexy for glottic carcinoma with fixation or impaired motion of the ...
23774619 - Mediastinal lymph-nodes metastasis beyond the lobe-specific: an independent risk factor...
24401019 - Diabetes is a major risk factor for mortality after lung transplantation.
18493499 - Photodynamic therapy for obstructive esophageal malignancies.
24649319 - Esophagitis resulting from treatment with crizotinib for anaplastic lymphoma kinase rea...
24303369 - Moderately escalated hypofractionated (chemo) radiotherapy delivered with helical inten...
17592299 - Staging systems for papillary thyroid carcinoma: a study of 2 tertiary referral centers.
24368339 - Subtypes of cytotoxic lymphocytes and natural killer cells infiltrating cancer nests co...
14998839 - Dysphagia following chemoradiation for locally advanced head and neck cancer.
Publication Detail:
Type:  Journal Article     Date:  2013-01-16
Journal Detail:
Title:  Medical oncology (Northwood, London, England)     Volume:  30     ISSN:  1559-131X     ISO Abbreviation:  Med. Oncol.     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-01-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9435512     Medline TA:  Med Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  370     Citation Subset:  IM    
Medical Oncology Division and Breast Unit, Sen. Antonio Perrino Hospital, S.S. 7, 72100, Brindisi, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  AC133 expression associated with poor prognosis in stage II colorectal cancer.
Next Document:  Radiochemotherapy and brachytherapy could be the standard treatment for anal canal cancer in elderly...